Viral haemorrhagic fever;Virale hemorragische koorts

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 9, 1998, Pages 448-452

  Kager, P A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DENGUE; DIFFERENTIAL DIAGNOSIS; HEMORRHAGIC FEVER; HUMAN; INFECTION PREVENTION; LASSA FEVER; MALARIA; NETHERLANDS; RICKETTSIOSIS; SEPSIS; VIRUS TRANSMISSION; YELLOW FEVER;

DENGUE; HEMORRHAGIC FEVER, EBOLA; HEMORRHAGIC FEVERS, VIRAL; HUMANS; LASSA FEVER; MARBURG VIRUS DISEASE; NETHERLANDS; TRAVEL; YELLOW FEVER;

EID: 0032574175     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jordans JGM, Groen J, Clement J, Letevre A. Osterhaus ADME. Infectie met het Hantavirus, een te weinig herkende oorzaak van acute merinsufficientie. Ned Tijdschr Geneeskd 1991;135:791-3.
2. Jordans JGM, Groen J, Clement J, Lefevre A, Haraldsdöttir V. Osterhaus ADME. Hantavirusinfecties in Twente. Ned Tijdschr Geneeskd 1991;135:796-8.
3. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997;3:95-104.
4. Okello GBA, Agata N, Ouma J, Cherogony SC, Tukei PM, Ochieng W, et al. Outbreak of yellowfever in Kenya [letter]. Lancet 1993; 341:489
5. Roberton SE, Hull BP, Tomori O, Bele O, LeDuc JW, Esteves K. Yellow fever a decade of reemergence. JAMA 1996;276:1157-62.
6. World Health Organization Yellow fever in a traveller. Wkly Epidemiol Rec 1996;71:342-3.
7. World Health Organization. Dengue and dengue haemorrhagic fever in the Americas, 1996. Wkly Epidemiol Rec 1997;72:123-3.
8. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989;11 (Suppl 4):S830-9.
9. Rosen L. The pathogenesis of dengue haemorrhagic fever. A critical appraisal of current hypotheses. S Afr Med J 1986;70 Suppl: 40-2.
10. Bakker RC, Veenstra J, Dingemans-Dumas AM. Wetsteyn JCFM, Kager PA. Imported dengue in the Netherlands. J Travel Med 1996;3:204-8
11. Clegg JCS. Possible approaches to a vaccine against Lassa fever. Trans R Soc Trop Med Hyg 1984;78:307-10.
12. Centers for Disease Control. Management of patients with suspected viral hemorrhagic fever. Morb Mortal Wkly Rep 1988;37 (Suppl 3):1-16.
13. Helmick CG, Webb PA, Scribner CL, Krebs JW, McCormick JB. No evidence for increased risk of Lassa fever infection in hospital staff. Lancet 1986;11:1202-5.
14. Fisher-Hoch SP, Tomori O, Nasidi A, Perez-Oronoz GI, Fakile Y, Hutwagner L, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995;311:857-9.
15. McCormick JB, King IJ, Webb PA, Scrihner CL, Craven RB, Johnson KM, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
16. Heide RM van der. Een patient met Lassakoorts uit Opper-Volta, herkend in Nederland. Ned Tijdschr Geneeskd 1982;126:566-9.
17. World Health Organization. Ebola haemorrhagic fever Wkly Epidemiol Rec 1995;70:241-2.
18. World Health Organization. Outbreak of Ebola haemorrhagic fever in Gabon officially declared over Wkly Epidemiol Rec 1996;71:125-6.
19. World Health Organization Ebola haemorrhagic fever. Wkly Epidemiol Rec 1996;71:359.
20. World Health Organization. Ebola haemorrhagic fever. Wkly Epidemiol Rec 1997;72:71
21. Le Guenno B, Formentry P, Wyers M, Gounon P, Walker F, Boesch C, Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995;345:1271-4.
22. Peters CJ, Sanchez A, Feldmann H, Rollin PE, Nichol S, Ksiazek TG. Filoviruses as emerging pathogens. Seminars in Virology 1994;5:147-54